Wissenschaftliche Arbeiten

Prof. Dr. Aysun Soysal

254 Publikationen. Neben jeder Publikation steht die Quelle der Angabe.

Zurück zum Profil

  1. Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression

    Computer Methods and Programs in Biomedicine, 2021

    DOI 10.1016/j.cmpb.2021.106180 PMID 34146771 31 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  2. Matrix metalloproteinases and their tissue inhibitors in relapsing remitting multiple sclerosis: Possible markers and treatment agents

    Ideggyogyaszati Szemle, 2021

    DOI 10.18071/isz.74.0050 PMID 33497055 3 Zitationen (Europe PMC) Quelle: ORCID

  3. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, 2021

    DOI 10.1212/wnl.0000000000012084 PMID 33879599 67 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  4. Occipital neuralgia as a presentation of multiple sclerosis

    Neurology Asia, 2021

    Quelle: ORCID

  5. The diagnostic and prognostic value of magnetic resonance imaging for evaluating atypical inflammatory demyelinating lesions,Atipik enflamatuvar demiyelinizan lezyonların değerlendirilmesinde manyetik rezonans görüntülemenin diagnostik ve prognostik önemi

    Turk Noroloji Dergisi, 2021

    DOI 10.4274/tnd.2021.00907 Frei zugänglicher VolltextQuelle: ORCID

  6. The effects of 30 HZ, 50 HZ and 100 HZ continuous theta burst stimulation via transcranial magnetic stimulation on the electrophysiological parameters in healthy individuals

    Ideggyogyaszati Szemle, 2021

    DOI 10.18071/isz.74.0041 PMID 33497056 9 Zitationen (Europe PMC) Quelle: ORCID

  7. The effects of supervised versus home Pilates-based core stability training on lower extremity muscle strength and postural sway in people with multiple sclerosis

    Multiple Sclerosis Journal, 2021

    DOI 10.1177/13524585211012202 PMID 33908294 17 Zitationen (Europe PMC) Quelle: ORCID

  8. The profile of a neurology clinic and malnutrition awareness,Bir nöroloji kliniğine yatan hasta profili ve malnütrisyon farkındalığı

    Turk Noroloji Dergisi, 2021

    DOI 10.4274/tnd.2020.75032 5 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  9. The use of Modified Rio score for determining treatment failure in patients with multiple sclerosis: retrospective descriptive case series study

    Acta Neurologica Belgica, 2021

    DOI 10.1007/s13760-020-01476-2 PMID 32865702 4 Zitationen (Europe PMC) Quelle: ORCID

  10. Transvers myelitis due to hsv-2 infection in an undiagnosed hiv positive patient,Tanı almamış hiv pozitif hastada hsv-2 enfeksiyonuna bağlı transvers miyelit

    Turk Noroloji Dergisi, 2021

    DOI 10.4274/tnd.2021.87259 2 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  11. Treatment Response Score to Glatiramer Acetate or Interferon Beta-1a

    Neurology, 2021

    DOI 10.1212/wnl.0000000000010991 PMID 33024022 11 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  12. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018

    CNS Drugs, 2021

    DOI 10.1007/s40263-021-00833-w PMID 34164782 7 Zitationen (Europe PMC) Quelle: ORCID

  13. 004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis

    BMJ Neurology Open, 2021

    DOI 10.1136/bmjno-2021-anzan.4 Frei zugänglicher VolltextQuelle: OpenAlex

  14. Disability Accrual in Primary Progressive & Secondary Progressive Multiple Sclerosis (2901)

    Neurology, 2021

    DOI 10.1212/wnl.96.15_supplement.2901 Quelle: OpenAlex

  15. Delay from treatment start to full effect of immunotherapies for multiple sclerosis (2679)

    Neurology, 2021

    DOI 10.1212/wnl.96.15_supplement.2679 Quelle: OpenAlex

  16. Variability of the Response to Immunotherapy Among Sub-groups of Patients With Multiple Sclerosis (4107)

    Neurology, 2021

    DOI 10.1212/wnl.96.15_supplement.4107 Quelle: OpenAlex

  17. Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant database

    Human Mutation, 2020

    DOI 10.1002/humu.24055 PMID 32579787 17 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

  18. Stimulus Duration in a Mixed Nerve Conduction Study: Decomposing Sensory Potential

    Turkish Journal Of Neurology, 2020

    DOI 10.4274/tnd.2020.28003 Frei zugänglicher VolltextQuelle: OpenAlex

  19. Cover, Volume 41, Issue 8

    Human Mutation, 2020

    DOI 10.1002/humu.24087 Quelle: OpenAlex

  20. Etiopathogenesis of pons infarction differs according to the localisation; A retrospective clinical trial

    Turkish Journal of Cerebrovascular Diseases, 2020

    DOI 10.5505/tbdhd.2020.48343 Frei zugänglicher VolltextQuelle: ORCID

  21. Comparison of Stroke Awareness Between Patient Relatives and Healthcare Professionals

    Medical Bulletin of Haseki, 2020

    DOI 10.4274/haseki.galenos.2019.5004 3 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID

  22. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

    Multiple Sclerosis and Related Disorders, 2020

    DOI 10.1016/j.msard.2019.101868 PMID 31877445 39 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  23. Comparing colored and white-black visual evoked potentials in multiple sclerosis patients,Multipl skleroz hastalarında siyah-beyaz ve renkli görsel uyandırılmış potansiyeller (GUP) kıyaslaması

    Noropsikiyatri Arsivi, 2020

    DOI 10.5152/npa.2017.22787 PMID 32550773 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  24. Delay from treatment start to full effect of immunotherapies for multiple sclerosis

    Brain, 2020

    DOI 10.1093/brain/awaa231 PMID 32947619 38 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  25. Does restricted diffusion in the splenium indicate an acute infarct?

    Acta Neurologica Belgica, 2020

    DOI 10.1007/s13760-017-0876-6 PMID 29307027 3 Zitationen (Europe PMC) Quelle: ORCID

  26. Early clinical markers of aggressive multiple sclerosis

    Brain, 2020

    DOI 10.1093/brain/awaa081 PMID 32386427 46 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  27. Longitudinal modeling of MS patient trajectories improves predictions of disability progression

    Arxiv, 2020

    DOI 10.48550/arxiv.2011.04749 Quelle: ORCID

  28. Marchiafava-bignami disease: Report of three cases,Marchiafava-bignami-betegseg: Harom eset ismertetese

    Ideggyogyaszati Szemle, 2020

    DOI 10.18071/isz.73.0065 PMID 32057207 1 Zitation (Europe PMC) Quelle: ORCID

  29. Prevalence And Impact Of Myofascial Pain Syndrome In Relapsing-Remitting Multiple Sclerosis And The Effects Of Local Anesthetic Injections For Short-Term Treatment

    Multiple Sclerosis and Related Disorders, 2020

    DOI 10.1016/j.msard.2020.102528 PMID 33022587 3 Zitationen (Europe PMC) Quelle: ORCID

  30. Risk of secondary progressive multiple sclerosis: A longitudinal study

    Multiple Sclerosis Journal, 2020

    DOI 10.1177/1352458519868990 PMID 31397221 66 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  31. The inflammatory markers and prognosis of cervicocephalic artery dissection: a stroke center study from a tertiary hospital

    Neurological Sciences, 2020

    DOI 10.1007/s10072-020-04699-6 PMID 32876776 2 Zitationen (Europe PMC) Quelle: ORCID

  32. To handle the handl syndrome through a case: The syndrome of headache with neurologic deficits and cerebrospinal fluid lymphocytosis,A handl szindróma - Fejfájás neurológiai hiánytünetekkel és a cerebrospinalis folyadék lymphocytosisával - Kezelése

    Ideggyogyaszati Szemle, 2020

    DOI 10.18071/isz.73.0135 PMID 32364341 1 Zitation (Europe PMC) Quelle: ORCID

  33. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis (2002)

    Neurology, 2020

    DOI 10.1212/wnl.94.15_supplement.2002 1 Zitation (OpenAlex) Quelle: OpenAlex

  34. Determinants of Therapeutic Lag in Multiple Sclerosis (2059)

    Neurology, 2020

    DOI 10.1212/wnl.94.15_supplement.2059 1 Zitation (OpenAlex) Quelle: OpenAlex

  35. Marchiafava-Bignami-betegség: három eset ismertetése

    Ideggyógyászati Szemle, 2020

    DOI 10.18071/isz.10.18071/isz.73.0065 Quelle: OpenAlex

  36. A Multicenter International Study to Evaluate Different Aspects of Relationship Between MS and Pregnancy

    Multiple Sclerosis and Related Disorders, 2020

    DOI 10.1016/j.msard.2019.11.012 Quelle: OpenAlex

  37. of Therapeutic Lag in Relapsing Multiple Sclerosis

    Document Server@UHasselt (UHasselt), 2020

    Quelle: OpenAlex

  38. Impulsivity In Idiopathic Parkinson Disease: Paired Case Control Study

    Abant Medical Journal, 2020

    DOI 10.47493/abantmedj.2020.1 Frei zugänglicher VolltextQuelle: OpenAlex

  39. Toksik ve Nutrisyonel Periferal Nöropatiler

    Turkiye Klinikleri Neurology - Special Topics, 2020

    Quelle: OpenAlex

  40. Predicting Long-Term Sustained Disability Progression in Multiple Sclerosis

    Document Server@UHasselt (UHasselt), 2020

    Quelle: OpenAlex

  41. Multipl Sklerozda Primer Baş Ağrısı Sıklığı:

    OSMANGAZİ JOURNAL OF MEDICINE, 2020

    DOI 10.20515/otd.778605 Frei zugänglicher VolltextQuelle: OpenAlex

  42. Impulsivity in multiple sclerosis: A paired case-control study

    Annals of Medical Research, 2020

    DOI 10.5455/annalsmedres.2020.02.158 Frei zugänglicher VolltextQuelle: OpenAlex

  43. Egzersiz; Multipl Sklerozdan Önce ve Multipl Sklerozdan Sonra İnflamasyon ve Onarımda Potansiyel Etkileri

    2020

    Quelle: OpenAlex

  44. Vgkc Encephalitis With Low-Titer Antibodies: Case Report

    Journal of Neurology Research Review & Reports, 2020

    DOI 10.47363/jnrrr/2020(2)118 Frei zugänglicher VolltextQuelle: OpenAlex

  45. Circulating B Cell Subsets and Cytokine Gene Expression Levels in Peripheral Blood and Skin Biopsy in Chronic Inflammatory Demyelinating Polyneuropathy (4119)

    Neurology, 2020

    DOI 10.1212/wnl.94.15_supplement.4119 Quelle: OpenAlex

  46. Identification of Therapeutic Lag in Multiple Sclerosis (1787)

    Neurology, 2020

    DOI 10.1212/wnl.94.15_supplement.1787 Quelle: OpenAlex

  47. Comparative analysis of fingolimod versus teriflunomide in relapsing–remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, 2019

    DOI 10.1016/j.msard.2019.101376 PMID 31473488 6 Zitationen (Europe PMC) Quelle: ORCID

  48. Early clinical markers of aggressive multiple sclerosis

    medRxiv, 2019

    DOI 10.1101/19002063 Frei zugänglicher VolltextQuelle: ORCID

  49. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

    Multiple Sclerosis and Related Disorders, 2019

    DOI 10.1016/j.msard.2019.01.003 PMID 30623864 41 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

  50. Profile of Syrian Asylum-Seekers from Neurological Clinic in a Tertiary Center

    European Neurology, 2019

    DOI 10.1159/000496807 PMID 30716733 7 Zitationen (Europe PMC) Quelle: ORCID